Modifiable Predictors of Neural Vulnerabilities for Obesity
Part of paid clinical trials in Lincoln, Nebraska.
- Sponsor
- University of Nebraska Lincoln
- Study ID
- NCT04522947
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 19 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Milkshake fMRI — OTHERWhile in the MRI scanner, the participant is shown a cue indicating the impending delivery of either milkshake or tasteless solution, followed by a brief blank screen, then delivery of the sip, and then a swallow cue. This procedure is repeated throughout the task.
Study Details
The purpose of this study is to examine patterns of neural activation in a priori selected brain regions associated with reward process during anticipation and delivery of appetizing food stimuli (milkshake sips) among young adults.
Key Dates
- Start date
- Oct 30, 2020
- Status verified
- Dec 2025
- Primary completion
- Apr 24, 2025
- Completion
- Apr 24, 2025
Study Design
- Enrollment
- 187 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- OTHER
Arms
- Experimental: fMRIParticipants are delivered sips of appetizing tastes (milkshake) and tasteless solution throughout the task while in the MRI scanner.
Primary Outcome Measure
Caudate Activation for Sip Cue [ Time Frame: 7 seconds after cue is presented ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Nebraska-Lincoln | Lincoln | Nebraska | 68588 | - |
Find similar trials in Lincoln, NE
By condition
By specialty
By research site
Related Studies
- A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)PHASE3 · Recruiting · Eli Lilly and Company · Ventura, California
- Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityPHASE3 · Recruiting · Amgen · Daphne, Alabama
- Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityPHASE3 · Recruiting · Amgen · Birmingham, Alabama
- A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)PHASE3 · Recruiting · Pfizer · Anaheim, California